Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Lenvatinib + Chemotherapy vs Pembrolizumab + Chemotherapy in Metastatic Esophageal Carcinoma
NCT04949256Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Jul 2021
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 25
01
Overview
A Phase 3 trial of lenvatinib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Merck & Co.. Started Jul 2021; status: terminated.
02
Drugs
lenvatinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04949256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04949256.